- Poster presentation
- Open Access
PReS-FINAL-2285: Pediatric non-renal SLE presenting as periorbital edema: response to treatment with belimumab
- B Arabshahi1
© Arabshahi et al.; licensee BioMed Central Ltd. 2013
Published: 5 December 2013
Periorbital edema without proteinuria is a rare and often difficult to manage manifestation of SLE. The use of belimumab for treatment of this complication has not been previously described in the pediatric literature.
To describe the use of belimumab for treatment of steroid-dependent chronic periorbital edema in new onset non-renal SLE.
Case report: A 16 year old white female presented with a three month history of periorbital edema in the setting of positive lupus serologies, synovitis, and hypocomplementemia. She had failed treatment with anti-histamines and had responded well to the use of oral steroids, but her symptoms quickly recurred upon tapering off steroids. Over the following six months, treatment with hydroxychloroquine and methotrexate failed to provide any steroid-sparing benefit. Addition of a three month trial of omalizumab also failed to provide any benefit. IV belimumab at 10 mg/kg monthly, was initiated and continued upon one year follow-up.
Treatment with belimumab resulted in complete resolution of the patient's periorbital edema, allowing her to discontinue the use of steroids within a month of starting this agent. No adverse reactions have been observed upon one-year follow up, and the patient's symptoms remain well controlled off steroids.
Belimumab may serve as a safe and effective steroid sparing agent for management periorbital edema associated with non-renal SLE.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.